First National Trust Co Has $8.40 Million Stock Holdings in Danaher Co. (NYSE:DHR)

First National Trust Co reduced its holdings in Danaher Co. (NYSE:DHR) by 6.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 36,292 shares of the conglomerate’s stock after selling 2,568 shares during the quarter. First National Trust Co’s holdings in Danaher were worth $8,396,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BKM Wealth Management LLC bought a new position in Danaher during the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at about $29,000. OFI Invest Asset Management bought a new position in shares of Danaher during the third quarter worth about $30,000. Rakuten Securities Inc. acquired a new position in shares of Danaher in the fourth quarter worth approximately $36,000. Finally, Financial Connections Group Inc. bought a new stake in Danaher in the fourth quarter valued at approximately $41,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on DHR. Barclays raised their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Raymond James increased their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Robert W. Baird raised their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, Royal Bank of Canada boosted their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $267.31.

Danaher Stock Up 0.6 %

Shares of DHR traded up $1.54 during trading hours on Friday, reaching $248.38. 1,787,817 shares of the stock traded hands, compared to its average volume of 2,914,990. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock has a fifty day simple moving average of $248.48 and a 200 day simple moving average of $232.27. The company has a market cap of $183.97 billion, a price-to-earnings ratio of 42.10, a PEG ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.36 EPS. On average, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date was Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Insider Transactions at Danaher

In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Danaher news, Director Alan G. Spoon sold 708 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joakim Weidemanis sold 22,433 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $250.46, for a total value of $5,618,569.18. Following the completion of the sale, the executive vice president now owns 90,412 shares in the company, valued at $22,644,589.52. The disclosure for this sale can be found here. Insiders have sold 107,273 shares of company stock worth $26,813,819 in the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.